Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:ENP) ) just unveiled an announcement.
Entropy Neurodynamics has filed a new U.S. provisional patent application covering psychedelic-assisted therapies for disorders of gut-brain interaction, expanding on its existing international and Australian IP for precision-controlled psilocybin and psilocin delivery. The filing draws on Phase 2a data from oral psilocybin in treatment-resistant irritable bowel syndrome patients, where a 75% response rate far exceeded current therapies, reinforcing the company’s U.S.-focused development and partnering strategy for TRP-8803 and bolstering its long-term exclusivity in a large, underserved gut-brain disorder market.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is a clinical-stage biotechnology company developing proprietary formulations of psilocin administered with psychotherapy to address diseases with significant unmet medical needs. Its lead program, TRP-8803, is an intravenous psilocin formulation designed to improve on oral psilocybin by accelerating onset, tightly controlling the depth and duration of the psychedelic state, and shortening treatment sessions to commercially viable timeframes.
Average Trading Volume: 2,282,021
Technical Sentiment Signal: Buy
Current Market Cap: A$60.38M
Find detailed analytics on ENP stock on TipRanks’ Stock Analysis page.